All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
The Committee for Medicinal Products for Human Use (CHMP) from the European Medicines Agency (EMA) has issued on Feb 25, 2021 a positive opinion for isatuximab (isa) in combination with carfilzomib and dexamethasone (Kd), for adult patients with multiple myeloma (MM) who had been previously treated with at least one line of therapy.1
The opinion was based on the results of the phase III IKEMA study (NCT03275285) in patients with MM who had received 1−3 lines of treatment. In this study, isatuximab combined with Kd was tested against Kd only. During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the interim trial analysis was presented.2 The primary endpoint of this study was progression-free survival (PFS), while overall response rate, very good partial response, and complete response were the secondary endpoints.
After a median follow-up of 20.7 months, patients in the isa-Kd group showed improved responses compared with the Kd group in all categories (Table 1).
Table 1. Outcomes in the IKEMA trial2
CR, complete response; d, dexamethasone; Isa, isatuximab; K, carfilzomib; MRD, measurable residual disease; VGPR, very good partial response. *MRD assessed by next-generation sequencing (NGS) at 10−5 sensitivity level. |
|||
Outcome |
Isa-Kd (n = 179) |
Kd (n = 123) |
p value |
---|---|---|---|
≥ VGPR, % |
72.6 |
56.1 |
0.0011 |
≥ CR, % |
39.7 |
27.6 |
|
MRD-negative*, % |
29.6 |
13 |
0.0004 |
MRD-negative + CR, % |
20.1 |
10.6 |
|
Overall, the median PFS with isa-Kd has not been reached, but was longer than with Kd, with a hazard ratio (HR) of 0.531 (99% CI, 0.318–0.889) favoring the triplet arm. More prolonged PFS survival was associated with achieving measurable residual disease (MRD) negativity in both treatment arms (Table 2), but still, isa-Kd achieved a greater PFS benefit for both MRD-negative and MRD-positive patients.
Table 2. PFS according to treatment groups and measurable residual disease status2
d, dexamethasone; Isa, isatuximab; K, carfilzomib; MRD, measurable residual disease. |
||
PFS |
HR |
95% CI |
---|---|---|
Isa-Kd MRD-negative |
0.578 |
0.052–6.405 |
Kd MRD-negative |
||
Isa-Kd MRD-positive |
0.670 |
0.452–0.993 |
Kd MRD-positive |
The combination of isa-Kd is not yet approved for usage in the EU; however, the final decision is expected in the coming months from the European Commission.
Isatuximab is an anti-CD38 monoclonal antibody that triggers apoptosis in MM cells and has immunomodulatory effects. It has so far been approved by the U.S. Food and Drug Administration (FDA) and the EMA in patients with relapsed/refractory MM who have been previously treated with at least two lines of therapy.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content